Mylan To Buy Agila Unit Of Strides For $1.6 Billion, But Pfizer, Otsuka Lurk
This article was originally published in PharmAsia News
Mylan said it would move to acquire the India-based Agila Specialties, a wholly owned subsidiary of Strides Arcolab, for $1.6 billion.
You may also be interested in...
Political tensions between Switzerland and the EU have led to concerns about the future status of the only Swiss medtech notified body, SQS. Here’s what SQS board member Daniel Taddeo said about the situation.
Agency officials determining needs using existing budgets before requesting more funds and will engage with tech investors for design advice.